Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
martedì, ottobre 27
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Bio-Rad Laboratories Inc
BIO
NYSE
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$376.16
3.73
1%
Ult. Agg.: Oct 27, 9:30 AM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Utili:
I risultati di Q3 2026 tra 8 giorni da adesso in mer nov 4th, dopo la chiusura del mercato
Bio-Rad Laboratories Financials
Bio-Rad Laboratories (BIO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Bio-Rad Laboratories Lowers FY2026 Sales Guidance of $2.506B-$2.596B vs $2.567B Est
Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.506 billion-$2.596 billion to $2.506 billion-$2.596 billion vs $2.567 billion estimate.
Benzinga Newsdesk
PRO
Bio-Rad Laboratories Q2 Adj. EPS $2.62 Beats $1.75 Estimate, Sales $651.000M Beat $623.989M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $2.62 per share which beat the analyst consensus estimate of $1.75 by 49.71 percent. This is a 0.38 percent increase over earnings of $2.61 per share from
Benzinga Newsdesk
PRO
Bio-Rad Laboratories Lowers FY2026 Sales Guidance from $2.596B-$2.622B to $2.506B-$2.596B vs $2.630B Est
Bio-Rad Laboratories (NYSE:BIO) lowers FY2026 sales outlook from $2.596 billion-$2.622 billion to $2.506 billion-$2.596 billion vs $2.630 billion estimate.
Benzinga Newsdesk
PRO
Bio-Rad Laboratories Q1 Adj. EPS $1.89 Misses $1.98 Estimate, Sales $592.100M Beat $588.875M Estimate
Bio-Rad Laboratories (NYSE:BIO) reported quarterly earnings of $1.89 per share which missed the analyst consensus estimate of $1.98 by 4.55 percent. This is a 25.59 percent decrease over earnings of $2.54 per share from
Benzinga Newsdesk
Earnings Scheduled For April 30, 2026
Benzinga Insights
PRO
Bio-Rad Laboratories Sees FY2026 Sales $2.596B-$2.622B vs $2.630B Est
Full-Year 2026 Financial OutlookBio-Rad is providing its financial outlook for the full-year 2026. The Company currently expects non-GAAP, currency neutral revenue growth of approximately 0.5 to 1.5 percent and an
Benzinga Newsdesk
